Cytodigm
Cytodigm
Cytodigm
Cytodigm
Cytodigm
Cytodigm
ABOUT US
WHO WE ARE
OUR TEAM
CAREERS & CULTURE
SCIENCE
DELIVERY TECHNOLOGIES
CYTOFINITY LNP PLATFORMS
PULMOFINITY LPP PLATFORM
INSIGHTS
PARTNERING
INVESTORS & MEDIA
CONTACT
Cytodigm
Cytodigm
ABOUT US
WHO WE ARE
OUR TEAM
CAREERS & CULTURE
SCIENCE
DELIVERY TECHNOLOGIES
CYTOFINITY LNP PLATFORMS
PULMOFINITY LPP PLATFORM
INSIGHTS
PARTNERING
INVESTORS & MEDIA
CONTACT
Category
Regular Page
Regular Page
,
Pulmofinity™: Exclusive lung tropism via systemic dosing
Systemic delivery of nucleic acid therapeutics has traditionally been challenged by preferential accumulation...
July 15, 2026
By
dev_team
Regular Page
,
Cytofinity™-SP: PEG-free LNP optimized for spleen and immune cell targeting
Many genetic therapies require efficient delivery to immune cells, but conventional lipid nanoparticles...
July 15, 2026
By
dev_team
Regular Page
,
Cytofinity™-OP: Highly efficient delivery to human retinal cells
Effective ocular gene delivery requires platforms capable of efficiently delivering genetic material to...
July 15, 2026
By
dev_team
Regular Page
,
Cytofinity™-LV: PEG-free LNP formulation optimized for liver targeting
PEG-lipids (polyethylene glycol) have long been a critical component of lipid nanoparticles (LNPs), helping...
July 15, 2026
By
dev_team
Regular Page
,
Cytofinity-IH: Efficient delivery of mRNA to the lungs via inhalation
Traditional LNPs tend to aggregate and lose their encapsulation efficiency (EE) during nebulization, limiting...
July 3, 2026
By
dev_team
up